3.88
3.24%
-0.13
Monte Rosa Therapeutics Inc stock is currently priced at $3.88, with a 24-hour trading volume of 43,858.
It has seen a -3.24% decreased in the last 24 hours and a -22.40% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.08 pivot point. If it approaches the $3.82 support level, significant changes may occur.
Previous Close:
$4.01
Open:
$3.99
24h Volume:
43,858
Market Cap:
$245.21M
Revenue:
-
Net Income/Loss:
$-135.35M
P/E Ratio:
-1.5097
EPS:
-2.57
Net Cash Flow:
$-62.84M
1W Performance:
-2.51%
1M Performance:
-22.40%
6M Performance:
-22.09%
1Y Performance:
-41.12%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
645 Summer Street, Suite 102, Boston
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-13-22 | Initiated | UBS | Buy |
Aug-15-22 | Initiated | Jefferies | Buy |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 ... - Yahoo Finance
Yahoo Finance
The Globe and Mail - The Globe and Mail
The Globe and Mail
Seed financing announcement for new ICR and Oxford spinout company Kodiform Therapeutics - The Institute of Cancer Research
The Institute of Cancer Research
Norges Bank Buys Shares of 447115 Telephone and Data Systems, Inc. (NYSE:TDS) - Defense World
Defense World
Top investors say Monte Rosa Therapeutics Inc (GLUE) ticks everything they need – Sete News - SETE News
SETE News
Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Yahoo Finance
Yahoo Finance
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Monte Rosa Therapeutics Inc (GLUE) Net Income 2024
GLUE net income (TTM) was -$135.35 million for the quarter ending December 31, 2023, a -24.75% decrease year-over-year.
Monte Rosa Therapeutics Inc (GLUE) Cash Flow 2024
GLUE recorded a free cash flow (TTM) of -$62.84 million for the quarter ending December 31, 2023, a +40.36% increase year-over-year.
Monte Rosa Therapeutics Inc (GLUE) Earnings per Share 2024
GLUE earnings per share (TTM) was -$2.63 for the quarter ending December 31, 2023, a -14.85% decline year-over-year.
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):